Want to see IN:TORNTPHARM full AI Analyst Report?
TORNTPHARM Stock Chart & Stats
₹4959.80
₹58.00(1.17%)
At close: 4:00 PM EDT
₹4959.80
₹58.00(1.17%)
Day’s Range― - ―
52-Week Range₹3,480.00 - ₹5,249.95
Previous CloseN/A
Volume267.59K
Average Volume (3M)7.49K
Market Cap
₹1.94T
Enterprise Value₹1.65M
Total Cash (Recent Filing)₹23.70B
Total Debt (Recent Filing)₹150.25B
Price to Earnings (P/E)79.5
Beta0.45
Next Earnings
Oct 28, 2026EPS Estimate
16.68Next Dividend Ex-DateN/A
Dividend Yield0.29%
Share Statistics
EPS (TTM)63.91
Shares Outstanding380,354,250
10 Day Avg. Volume2,743
30 Day Avg. Volume7,494
Financial Highlights & Ratios
PEG Ratio5.00
Price to Book (P/B)17.02
Price to Sales (P/S)10.22
P/FCF Ratio73.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)69.8
Revenue Forecast (FY)₹194.72B
Bulls Say, Bears Say
Bulls Say
Multi-year Revenue GrowthSustained revenue growth over multiple years indicates durable demand for branded generics and successful market execution. This scale expansion supports long-term investment in sales/marketing, widens distribution reach, and creates a structural base for future product launches and international growth.
Improving ProfitabilityRising net and stable operating margins reflect improved pricing power, better product mix, or cost control that are sustainable drivers of free cash flow. Higher margins increase ability to fund R&D, marketing and capex, strengthening competitive position over the medium term.
Stronger Capital StructureMaterial reduction in leverage enhances resilience to shocks, lowers interest burden, and preserves funding optionality for M&A or capex. A healthier balance sheet supports credit profiles and reduces refinancing risk, benefiting long-term strategic flexibility.
Bears Say
Sharp FY2026 Asset JumpA large unexplained asset increase impairs trend comparability and raises potential asset-quality or accounting-structure questions. This complicates forecasting returns and could hide impairments or acquisitions that alter capital intensity and future profitability metrics.
Volatile Cash ConversionUneven cash conversion and volatile free cash flow growth reduce predictability of internally generated funds for dividends, buybacks or investments. Structural working-capital swings or inconsistent OCF can limit ability to sustain long-term capital allocation plans.
Margin Volatility / Gross Margin DropA sharp gross-margin decline signals exposure to cost inflation, pricing pressure, or adverse mix shifts that can erode durable profitability. If persistent, margin pressure will force strategic responses (price increases, cost cuts, product repricing) that may weaken competitive positioning.
Torrent Pharmaceuticals Ltd News
TORNTPHARM FAQ
What was Torrent Pharmaceuticals Ltd’s price range in the past 12 months?
Torrent Pharmaceuticals Ltd lowest stock price was ₹3480.00 and its highest was ₹5249.95 in the past 12 months.
What is Torrent Pharmaceuticals Ltd’s market cap?
Torrent Pharmaceuticals Ltd’s market cap is ₹1.94T.
When is Torrent Pharmaceuticals Ltd’s upcoming earnings report date?
Torrent Pharmaceuticals Ltd’s upcoming earnings report date is Oct 28, 2026 which is in 85 days.
How were Torrent Pharmaceuticals Ltd’s earnings last quarter?
Torrent Pharmaceuticals Ltd released its earnings results on Jul 30, 2026. The company reported ₹15.4 earnings per share for the quarter, beating the consensus estimate of ₹14.95 by ₹0.45.
Is Torrent Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Torrent Pharmaceuticals Ltd’s price is currently Overvalued.
Does Torrent Pharmaceuticals Ltd pay dividends?
Torrent Pharmaceuticals Ltd pays a Semiannually dividend of ₹9 which represents an annual dividend yield of 0.29%. See more information on Torrent Pharmaceuticals Ltd dividends here
What is Torrent Pharmaceuticals Ltd’s EPS estimate?
Torrent Pharmaceuticals Ltd’s EPS estimate is 16.68.
How many shares outstanding does Torrent Pharmaceuticals Ltd have?
Torrent Pharmaceuticals Ltd has 380,354,250 shares outstanding.
What happened to Torrent Pharmaceuticals Ltd’s price movement after its last earnings report?
Torrent Pharmaceuticals Ltd reported an EPS of ₹15.4 in its last earnings report, beating expectations of ₹14.95. Following the earnings report the stock price went down -0.138%.
Which hedge fund is a major shareholder of Torrent Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in IN:TORNTPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity, managing the entire process from the discovery and development of generic drug formulations to their production and distribution. Its commercial activities extend across key markets such as India, the United States, Germany, and Brazil, alongside various other international territories. The company boasts a broad product catalog, offering treatments for a wide array of medical conditions. This includes therapies for cardiovascular diseases, central nervous system disorders, gastrointestinal issues, women's health concerns, diabetes, pain management, gynecological ailments, oncology, and anti-infective medications. Additionally, Torrent Pharma supplies essential vitamins, minerals, and other nutritional supplements. Beyond its proprietary offerings, the firm also provides contract manufacturing services to other companies. During the COVID-19 pandemic, it demonstrated its commitment by securing licensing agreements for crucial treatments like Baricitinib, Molnupiravir, and Paxlovid. Established in 1959, the company originally operated under the name Trinity Laboratories before officially becoming Torrent Pharmaceuticals Limited in 1971. Its corporate headquarters are located in Ahmedabad, India. Ultimately, Torrent Pharmaceuticals Limited functions as a subsidiary of Torrent Investments Private Limited.
Technical Analysis
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Mankind Pharma Ltd.
―
Sun Pharmaceutical Industries Limited
―
Zydus Lifesciences Limited
―







